BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 12937837)

  • 1. Prevalence and prognostic value of c-erbB2 expression in non-small cell lung cancer (NSCLC).
    Turken O; Kunter E; Cermik H; Isitmangil T; Kandemir G; Yaylaci M; Ozturk A
    Neoplasma; 2003; 50(4):257-61. PubMed ID: 12937837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
    Kasimir-Bauer S; Schleucher N; Weber R; Neumann R; Seeber S
    Oncol Rep; 2003; 10(2):475-82. PubMed ID: 12579292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MUC4 expression and its relation to ErbB2 expression, apoptosis, proliferation, differentiation, and tumor stage in non-small cell lung cancer (NSCLC).
    Karg A; Dinç ZA; Başok O; Uçvet A
    Pathol Res Pract; 2006; 202(8):577-83. PubMed ID: 16814944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
    Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
    Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
    Wang Y; Zhang XR; Fu J; Tan W; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].
    Cheng C; Wu YL; Gu LJ; Chen G; Weng YM; Feng WN; Zhong WZ
    Ai Zheng; 2005 Jul; 24(7):846-9. PubMed ID: 16004813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis.
    Yaren A; Oztop I; Kargi A; Ulukus C; Onen A; Sanli A; Binicier O; Yilmaz U; Alakavuklar M
    Int J Clin Pract; 2006 Jun; 60(6):675-82. PubMed ID: 16805752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
    Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
    Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer.
    Han CH; Cho JY; Moon JT; Kim HJ; Kim SK; Shin DH; Chang J; Ahn CM; Kim SK; Chang YS
    Oncol Rep; 2006 Dec; 16(6):1205-10. PubMed ID: 17089038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer.
    Imai H; Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
    Histopathology; 2009 Jun; 54(7):804-13. PubMed ID: 19635099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
    Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
    Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients.
    Timotheadou E; Skarlos DV; Samantas E; Papadopoulos S; Murray S; Skrickova J; Christodoulou C; Papakostantinou C; Pectasides D; Papakostas P; Kaplanova J; Vrettou E; Karina M; Kosmidis P; Fountzilas G
    Anticancer Res; 2007; 27(6C):4481-9. PubMed ID: 18214064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor markers as prognostic factors in treated non-small cell lung cancer.
    Trapé J; Buxo J; Pérez de Olaguer J; Vidal C
    Anticancer Res; 2003; 23(5b):4277-81. PubMed ID: 14666638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
    Sève P; Isaac S; Trédan O; Souquet PJ; Pachéco Y; Pérol M; Lafanéchère L; Penet A; Peiller EL; Dumontet C
    Clin Cancer Res; 2005 Aug; 11(15):5481-6. PubMed ID: 16061864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.
    Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
    Cancer Invest; 2006 Oct; 24(6):576-80. PubMed ID: 16982461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic analysis of stage III-IV non-small cell lung cancer patients treated by traditional chinese medicine].
    Zhou DH; Lin LZ; Zhou YQ; Luo RC; Liu KF; Jia YJ; Chen JY; Niu XW; Su BR; Lu J; Wang ST
    Ai Zheng; 2005 Oct; 24(10):1252-6. PubMed ID: 16219143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
    Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
    Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin A and Cyclin E expression in resected non-small cell lung cancer stage I-IIIA.
    Kosacka M; Piesiak P; Porebska I; Korzeniewska A; Dyla T; Jankowska R
    In Vivo; 2009; 23(4):519-25. PubMed ID: 19567385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Retinoid expression (RARbeta and CRBP1) in non-small-cell lung carcinoma].
    Mauro LV; Dalurzo M; Smith D; Lastiri J; Vasallo B; Joffei EB; Pallotta MG; Puricelli L
    Medicina (B Aires); 2008; 68(3):205-12. PubMed ID: 18689151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.